Are you Dr. Bazinet?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 4 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
1515 Holcombe Blvd
Houston, TX 77030Phone+1 713-792-6161
Education & Training
McGill University Faculty of MedicineClass of 2014
Certifications & Licensure
TX State Medical License 2023 - 2024
Publications & Presentations
PubMed
- Mayo Genetic Risk Models for Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax + Hypomethylating Agent.Naseema Gangat, Azeem Elbeih, Nour Ghosoun, Kristen McCullough, Fnu Aperna
American Journal of Hematology. 2024-12-13 - 1 citationsA phase I study of the myeloid cell leukemia 1 (MCL1) inhibitor tapotoclax (AMG 176) in patients with myelodysplastic syndromes after hypomethylating agent failure.Kelly S Chien, Juan Jose Rodriguez-Sevilla, Yesid Alvarado, Guillermo Montalban-Bravo, Danielle E Hammond
Leukemia Research. 2024-12-01 - Outcomes of Patients With Newly Diagnosed AML and Hyperleukocytosis.Fadi G Haddad, Koji Sasaki, Jayastu Senapati, Lianchun Xiao, Grace Park
JCO Oncology Practice. 2024-12-01
Press Mentions
MD Anderson Research Highlights for March 20, 2024March 21st, 2024- MD Anderson Research Highlights for April 12, 2024April 13th, 2024
